Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...

along with any side effects they may have. DPP-4 inhibitors help lower blood sugar levels only when they’re elevated. They do this by blocking the action of an enzyme called dipeptidyl peptidase ...

SGLT-2 inhibitor use vs DPP-4 inhibitor use was associated with lower incidence of epilepsy among patients with type 2 diabetes.

Diabetes is a growing concern in South Africa, with the country seeing a significant rise in the number of individuals diagnosed with the condition. Managing diabetes effectively requires a ...